A Randomized, Double-blind, Placebo-controlled, Dose-increasing Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Infusion of LPM3480392 Injection in Healthy Subject
Latest Information Update: 19 May 2023
At a glance
- Drugs LY 03014 (Primary)
- Indications Cancer pain; Postoperative pain
- Focus Adverse reactions
- Sponsors Luye Pharma Group
Most Recent Events
- 19 May 2023 New trial record